Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nathanael Gray
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
C4 Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Please see attachment.
Targeting ALK through Degradation and Allosteric Inhibitors
Project Narrative Lung cancer patients whose tumors harbor chromosomal rearrangements in ALK can be effectively treated with kinase inhibitors, including crizotinib. All patients ultimately develop acquired drug resistance and new therapies are urgently needed. The studies in this proposal will develop a new kind of ALK drug that causes ALK to be degraded instead of inhibited. We will explore whether this new strategy for drugging ALK is advantageous relative to existing ALK-targeted agents.
Filed on December 06, 2018.
Tell us what you know about Nathanael Gray's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nathanael Gray filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $100,000 - $149,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.